Literature DB >> 18820665

Brachyury, SOX-9, and podoplanin, new markers in the skull base chordoma vs chondrosarcoma differential: a tissue microarray-based comparative analysis.

Gerard J Oakley1, Kim Fuhrer, Raja R Seethala.   

Abstract

The distinction between chondrosarcoma and chordoma of the skull base/head and neck is prognostically important; however, both have sufficient morphologic overlap to make delineation difficult. As a result of gene expression studies, additional candidate markers have been proposed to help in separating those entities. We sought to evaluate the performance of new markers: brachyury, SOX-9, and podoplanin alongside the more traditional markers glial fibrillary acid protein, carcinoembryonic antigen, CD24, and epithelial membrane antigen. Paraffin blocks from 103 skull base/head and neck chondroid tumors from 70 patients were retrieved (1969-2007). Diagnoses were made based on morphology and/or whole-section immunohistochemistry for cytokeratin and S100 protein yielding 79 chordomas (comprising 45 chondroid chordomas and 34 conventional chordomas), and 24 chondrosarcomas. A tissue microarray containing 0.6 mm cores of each tumor in triplicate was constructed using a manual array (MTA-1; Beecher Instruments). For visualization of staining, the ImmPRESS detection system (Vector Laboratories) with 2-diaminobenzidine substrate was used. Sensitivities and specificities were calculated for each marker. Core loss from the microarray ranged from 25 to 29% yielding 66-78 viable cases per stain. The classic marker, cytokeratin, still has the best performance characteristics. When combined with brachyury, accuracy improves slightly (sensitivity and specificity for detection of chordoma 98 and 100%, respectively). Positivity for both epithelial membrane antigen and AE1/AE3 had a sensitivity of 90% and a specificity of 100% for detecting chordoma in this study. SOX-9 is apparently common to both notochordal and cartilaginous differentiation, and is not useful in the chordoma-chondrosarcoma differential diagnosis. Glial fibrillary acid protein, carcinoembryonic antigen, CD24, and epithelial membrane antigen did not outperform other markers, and are less useful in the diagnosis of chordoma vs chondrosarcoma. Podoplanin still remains the only positive marker for chondrosarcoma, though its accuracy is less than previously reported.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18820665      PMCID: PMC4233461          DOI: 10.1038/modpathol.2008.144

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  48 in total

1.  Tissue microarray is inappropriate for analysis of BCL6 expression in diffuse large B-cell lymphoma.

Authors:  Johan Linderoth; Mats Ehinger; Måns Akerman; Eva Cavallin-Ståhl; Gunilla Enblad; Martin Erlanson; Mats Jerkeman
Journal:  Eur J Haematol       Date:  2007-08       Impact factor: 2.997

2.  CD24 is expressed specifically in the nucleus pulposus of intervertebral discs.

Authors:  Nobuyuki Fujita; Takeshi Miyamoto; Jun-ichi Imai; Naobumi Hosogane; Toru Suzuki; Mitsuru Yagi; Kozo Morita; Ken Ninomiya; Kana Miyamoto; Hironari Takaishi; Morio Matsumoto; Hideo Morioka; Hiroo Yabe; Kazuhiro Chiba; Shinya Watanabe; Yoshiaki Toyama; Toshio Suda
Journal:  Biochem Biophys Res Commun       Date:  2005-11-10       Impact factor: 3.575

3.  Chondrosarcoma of the base of the skull: a clinicopathologic study of 200 cases with emphasis on its distinction from chordoma.

Authors:  A E Rosenberg; G P Nielsen; S B Keel; L G Renard; M M Fitzek; J E Munzenrider; N J Liebsch
Journal:  Am J Surg Pathol       Date:  1999-11       Impact factor: 6.394

4.  Sox9 is required for notochord maintenance in mice.

Authors:  Francisco Barrionuevo; Makoto M Taketo; Gerd Scherer; Andreas Kispert
Journal:  Dev Biol       Date:  2006-05-06       Impact factor: 3.582

5.  Chordoma and chondrosarcoma of the cranial base: an 8-year experience.

Authors:  C N Sen; L N Sekhar; V L Schramm; I P Janecka
Journal:  Neurosurgery       Date:  1989-12       Impact factor: 4.654

6.  Chordomas and chondrosarcomas of the skull base: comparative analysis of clinical results in 30 patients.

Authors:  Young Hyun Cho; Jeong Hoon Kim; Shin Kwang Khang; Jung-Kyo Lee; Chang Jin Kim
Journal:  Neurosurg Rev       Date:  2007-10-09       Impact factor: 3.042

7.  Chordoma. Antibodies to epithelial membrane antigen and carcinoembryonic antigen in differential diagnosis.

Authors:  M Miettinen
Journal:  Arch Pathol Lab Med       Date:  1984-11       Impact factor: 5.534

8.  Differential diagnosis of chordoma, chondroid, and ependymal tumors as aided by anti-intermediate filament antibodies.

Authors:  M Miettinen; V P Lehto; D Dahl; I Virtanen
Journal:  Am J Pathol       Date:  1983-08       Impact factor: 4.307

Review 9.  Chondroid chordoma. A hyalinized chordoma without cartilaginous differentiation.

Authors:  P B Jeffrey; C G Biava; R L Davis
Journal:  Am J Clin Pathol       Date:  1995-03       Impact factor: 2.493

10.  Chordomas and chondrosarcomas of the cranial base: results and follow-up of 60 patients.

Authors:  E Gay; L N Sekhar; E Rubinstein; D C Wright; C Sen; I P Janecka; C H Snyderman
Journal:  Neurosurgery       Date:  1995-05       Impact factor: 4.654

View more
  41 in total

1.  CORR(®) Tumor Board: Sacral Insufficiency Fractures are Common After High-dose Radiation for Sacral Chordomas Treated With or Without Surgery.

Authors:  Megan E Anderson; Jim S Wu; Sara O Vargas
Journal:  Clin Orthop Relat Res       Date:  2015-12-07       Impact factor: 4.176

Review 2.  Recurrent skeletal extra-axial chordoma confirmed with brachyury: imaging features and review of the literature.

Authors:  Joshua E Lantos; Narasimhan P Agaram; John H Healey; Sinchun Hwang
Journal:  Skeletal Radiol       Date:  2013-05-09       Impact factor: 2.199

Review 3.  The notochord: structure and functions.

Authors:  Diana Corallo; Valeria Trapani; Paolo Bonaldo
Journal:  Cell Mol Life Sci       Date:  2015-04-02       Impact factor: 9.261

4.  The prognostic value of Ki-67, p53, epidermal growth factor receptor, 1p36, 9p21, 10q23, and 17p13 in skull base chordomas.

Authors:  Craig Horbinski; Gerard J Oakley; Kathleen Cieply; Geeta S Mantha; Marina N Nikiforova; Sanja Dacic; Raja R Seethala
Journal:  Arch Pathol Lab Med       Date:  2010-08       Impact factor: 5.534

5.  Neck pain in a 27-year-old man.

Authors:  Addisu Mesfin; Jacob M Buchowski; Mitra Mehrad; Jianwen Xu
Journal:  Clin Orthop Relat Res       Date:  2013-02-15       Impact factor: 4.176

6.  Derivation and characterization of an extra-axial chordoma cell line (EACH-1) from a scapular tumor.

Authors:  Amalia M DeComas; Patrice Penfornis; Michael R Harris; Mark S Meyer; Radhika R Pochampally
Journal:  J Bone Joint Surg Am       Date:  2010-05       Impact factor: 5.284

Review 7.  Ear and Temporal Bone: Cartilaginous and Osseous Pathologies.

Authors:  Amarpreet Sabharwal; Kelly R Magliocca; Michelle D Williams
Journal:  Head Neck Pathol       Date:  2018-08-01

Review 8.  Chordoma of the Head and Neck: A Review.

Authors:  Jason K Wasserman; Denis Gravel; Bibianna Purgina
Journal:  Head Neck Pathol       Date:  2017-10-04

9.  UM-Chor1: establishment and characterization of the first validated clival chordoma cell line.

Authors:  John Henry Owen; Christine M Komarck; Anthony C Wang; Waleed M Abuzeid; Richard F Keep; Erin L McKean; Stephen Sullivan; Xing Fan; Mark E P Prince
Journal:  J Neurosurg       Date:  2017-04-21       Impact factor: 5.115

10.  Markers aiding the diagnosis of chondroid tumors: an immunohistochemical study including osteonectin, bcl-2, cox-2, actin, calponin, D2-40 (podoplanin), mdm-2, CD117 (c-kit), and YKL-40.

Authors:  Søren Daugaard; Lise H Christensen; Estrid Høgdall
Journal:  APMIS       Date:  2009-07       Impact factor: 3.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.